[
  {
    "ts": "2026-01-16T03:15:53+00:00",
    "headline": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
    "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
    "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bcd9de05-aef9-38cf-b319-2387897ab0ad",
      "content": {
        "id": "bcd9de05-aef9-38cf-b319-2387897ab0ad",
        "contentType": "STORY",
        "title": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
        "description": "",
        "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
        "pubDate": "2026-01-16T03:15:53Z",
        "displayTime": "2026-01-16T03:15:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORIC"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]